

## Regimen Reference Order

### GYNE – bevacizumab + pegylated liposomal DOXOrubicin

ARIA: GYNE - [bev + doxorubicin (peg-liposomal)]

Planned Course: Every 28 days until disease progression or unacceptable toxicity

Indication for Use: Ovarian Cancer Platinum-Resistant

CVAD: At Provider’s Discretion

<p><b><u>Proceed with treatment if:</u></b></p> <p><b><u>Cycle 1</u></b></p> <p><b><u>Day 1 only</u></b></p> <p><b>ANC equal to or greater than <math>1.5 \times 10^9/L</math> AND Platelets equal to or greater than <math>100 \times 10^9/L</math></b></p> <p><b><u>Cycle 2 and Onwards</u></b></p> <p><b><u>Day 1 only</u></b></p> <p><b>ANC equal to or greater than <math>1.2 \times 10^9/L</math> AND Platelets equal to or greater than <math>75 \times 10^9/L</math></b></p> <p style="text-align: center;">❖ Contact Physician if parameters not met</p>
---

#### SEQUENCE OF MEDICATION ADMINISTRATION

Pre-treatment Requirements		
Drug	Dose	CCMB Administration Guideline
Not Applicable		

Treatment Regimen – GYNE – bevacizumab + pegylated liposomal DOXOrubicin		
Drug	Dose	CCMB Administration Guideline
<b>Day 1</b>		
<b>Establish primary solution 500 mL of: normal saline (bevacizumab incompatible with D5W)</b>		
bevacizumab (brand name specific)	10 mg/kg	IV in normal saline 100 mL over 20 minutes <i>*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order</i>
<b>Establish primary solution 500 mL of: D5W (pegylated liposomal DOXOrubicin incompatible with normal saline)</b>		
dexamethasone	8 mg	Orally 30 minutes pre-chemotherapy
pegylated liposomal DOXOrubicin	40 mg/m <sup>2</sup>	IV in D5W 250 mL over 90 minutes <b>OR</b> IV in D5W 500 mL over 2 hours if dose is greater than or equal to 90 mg <i>(Maximum rate 1 mg/minute)</i> If no reaction, subsequent doses may be administered over 60 minutes

Day 15		
Establish primary solution 500 mL of: normal saline		
bevacizumab (brand name specific)	10 mg/kg	IV in normal saline 100 mL over 20 minutes <i>*Alert: Ensure brand name on prescription label (indicated in brackets on prescription label) matches prescribed order</i>
All doses will be automatically rounded that fall within the DSG Approved Dose Bands. See GYNE DSG – Dose Banding document for more information		

In the event of an infusion-related hypersensitivity reaction, refer to the ‘Hypersensitivity Reaction Standing Order’

## REQUIRED MONITORING

All Cycles

Day 1

- CBC, serum creatinine, liver enzymes, urine protein and blood pressure as per Physician Orders
  - Urinalysis for protein: Where urinalysis is not possible, use dipstick. If lab urinalysis for protein is greater than or equal to 1 g/L or dipstick proteinuria shows 2+ or 3+, notify prescriber
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O<sub>2</sub> saturation) at baseline and as clinically indicated
- No observation period is required after bevacizumab or after pegylated liposomal DOXOrubicin administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

Day 15

- No blood work required on Day 15
- Full vital signs (temperature, heart rate, respiratory rate, blood pressure and O<sub>2</sub> saturation) at baseline and as clinically indicated
- No observation period is required after bevacizumab administration. Patient can be discharged from treatment room if stable whether they had a reaction or not

## Recommended Support Medications

Drug	Dose	CCMB Administration Guideline
metoclopramide	10 – 20 mg	Orally every 4 hours as needed for nausea and vomiting

## DISCHARGE INSTRUCTIONS

- Patients should be instructed to contact their cancer team immediately if symptoms of hypersensitivity reactions occur after discharge
- Instruct patient to continue taking anti-emetic(s) at home
- Reinforce applicable safe handling precautions of medications, blood and body fluids for 48 hours after completion of chemotherapy

## ADDITIONAL INFORMATION

- bevacizumab can cause increased risk of hypertension, post-operative bleeding, wound healing complications and thromboembolic events
- bevacizumab is available from more than one manufacturer and uses several different brand names. Brand name will be indicated in brackets after bevacizumab. **Ensure prescription label matches the brand name on prescribed order**